IN Brief:
- CoreNhanced Biotechnology Limited will serve as CoreFX’s European scientific and commercial headquarters.
- The County Cork operation is being developed alongside Teagasc Moorepark with Enterprise Ireland support.
- Initial work centres on bioactive stability, functionality, sensory performance and manufacturing efficiency.
CoreFX Ingredients has established CoreNhanced Biotechnology Limited in County Cork as its European headquarters for scientific innovation, technology development and commercial expansion. The operation is being developed with support from Enterprise Ireland and in collaboration with Teagasc Moorepark, placing a US ingredient-technology business inside one of Ireland’s main food research environments.
The Irish base launches with a three-person scientific team comprising a senior scientist, scientist and junior scientist. Trevor Dunne, CoreFX’s managing director for Europe, will lead commercial growth, customer partnerships and expansion across the region. Enterprise Ireland has worked with the company since 2023 on its European strategy, while Teagasc provides access to food-science and product-development capabilities at Moorepark.
CoreFX is building the operation around its CoreNhanced technology platform, which is intended to improve the stability, functionality and sensory performance of bioactive ingredients during manufacture and storage. The work also targets manufacturing efficiency, placing the programme between ingredient formulation and process engineering rather than treating nutritional value as separate from the way a product is made.
That distinction is important for ingredients whose performance can deteriorate through heat, oxygen, moisture, shear or interactions with other components in a formulation. A bioactive may be analytically effective in isolation but create flavour, texture or stability problems when it is introduced into a beverage, powder, bar or other finished product. Manufacturers then have to compensate through protective systems, over-formulation or process changes that can add cost and complexity.
The Moorepark location gives CoreFX a route to test those constraints alongside broader food-development work. Teagasc’s programme covers food science, nutrition, ingredients, product development and commercialisation, allowing formulation work to move into pilot-scale processing rather than stopping at bench chemistry. That can expose failures in mixing, heat treatment, storage or sensory performance before a customer reaches full production.
The expansion also reflects the increasing overlap between food ingredients and biotechnology. Functional products are moving beyond simple fortification towards systems in which value depends on controlled delivery, stability or improved bioavailability. That creates additional engineering questions around encapsulation, dispersion, particle size, solubility and the sequence in which ingredients are introduced on the line.
Recent ingredient development has exposed the same constraints from different directions. Creatine beverages have had to address stability in liquid systems, while newer protein ingredients are being engineered around solubility, flavour and clarity to enter applications that conventional isolates struggle to serve. CoreFX is approaching those problems as a platform business, with the Irish operation intended to work across multiple bioactive compounds and product types.
Europe gives the company access to a dense base of food, nutrition and ingredient manufacturers alongside regulatory requirements that can shape formulation and claims. Ireland adds an established dairy, food-science and biotechnology cluster, while the Teagasc relationship provides technical infrastructure without CoreFX having to reproduce every pilot capability inside its own premises.
The scale of the investment has not been disclosed, and the initial scientific headcount is modest. That makes the quality of resulting programmes more informative than the size of the announcement. A research headquarters earns its industrial relevance when technologies move into repeatable customer processes, survive scale-up and generate specifications that plants can run without extensive adjustment.
Scale-up is often where ingredient platforms lose momentum. Laboratory batches can be produced under tightly controlled conditions with carefully selected raw materials, but commercial lines introduce larger residence times, equipment limitations, variable feedstocks and stricter throughput targets. Stability and sensory performance must remain consistent while the process becomes faster, cheaper and easier to reproduce.
The CoreFX model should also benefit from putting commercial and technical functions close together. Customer problems can be translated into research programmes earlier, while scientists gain a clearer view of the processing and cost constraints that determine whether a formulation is commercially useful. That reduces the risk of developing an elegant ingredient system that is too difficult or expensive to manufacture at scale.
CoreFX describes Ireland as part of a longer-term international growth strategy rather than a standalone laboratory project. The next milestones will be validated ingredient systems, customer programmes and commercial launches emerging from the Moorepark work. Those outcomes will show whether the new headquarters can turn broad claims around bioactive performance into repeatable production results across European food and nutrition manufacturing.
The arrangement also gives Enterprise Ireland and Teagasc a route to anchor more applied ingredient development in the region. If customer projects progress from formulation through pilot validation to commercial manufacture, the value of the base will be measured in technology transfer and production adoption rather than research activity alone.
